西安交通大学学报（医学版）2026，Vol.47Issue(1)：62-68,7.DOI:10.7652/jdyxb202601009
生物标志物检测在阿尔茨海默病Aβ免疫治疗中的应用
Optimizing biomarker assessment for anti-amyloid immunotherapy in Alzheimer's disease
摘要
Abstract
Although amyloid-beta positron emission tomography(Aβ-PET)and cerebrospinal fluid(CSF)biomarkers have both demonstrated excellent performance in detecting Alzheimer's disease(AD)pathology,current evidence suggests that their underlying biological mechanisms and clinical utilities in diagnosis and therapeutic monitoring are not entirely equivalent.With the advent of novel disease-modifying therapies,the clinical use of Aβ biomarkers has evolved from traditional binary classification used to determine treatment eligibility to monitoring treatment efficacy.In light of the increasingly widespread adoption of PET and CSF biomarkers,accurate interpretation of results is paramount.Misinterpretation may lead to misdiagnosis and impose additional burdens on patients.A comprehensive understanding of their respective strengths,limitations,and distinctions of different biomarker modalities can facilitate the selection of the optimal biomarker modality based on the clinical context and the robustness of local testing methods.This is essential to minimizing diagnostic errors and guide the safe and precise administration of anti-Aβ monoclonal antibody therapy.关键词
阿尔茨海默病(AD)/β-淀粉样蛋白(Aβ)沉积/免疫治疗/抗Aβ单克隆抗体治疗Key words
Alzheimer's disease(AD)/amyloid-beta(Aβ)deposition/immunotherapy/anti-amyloid monoclonal antibody therapy分类
医药卫生引用本文复制引用
陈帅,邵靖雨,张杰文..生物标志物检测在阿尔茨海默病Aβ免疫治疗中的应用[J].西安交通大学学报（医学版）,2026,47(1):62-68,7.基金项目
河南省2025年重点研发计划项目(No.241111313500) （No.241111313500）
河南省2025年国际科技合作项目(No.252102521060)Supported by the Henan Provincial Key R&D Program(No.241111313500)and the Henan Provincial International Science and Tech-nology Cooperation Project(No.252102521060) （No.252102521060）
